The Clatterbridge Cancer Centre

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Head and neck cancer3 trials
• Lung cancer3 trials
• Pancreatic cancer3 trials
• Melanoma2 trials
• Multiple myeloma2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Gastric and oesophageal cancer1 trial
• Metastatic breast cancer1 trial
• Myeloproliferative neoplasms1 trial
• Neuroendocrine tumours1 trial

Phase

• Phase 36 trials
• Phase 1/23 trials
• Phase 2/33 trials
• Phase 12 trials
• Phase 22 trials

Status

• Recruiting9 trials
• Active, not recruiting5 trials
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• Janssen Research & Development, LLC4 trials
• BioNTech SE2 trials
• Revolution Medicines, Inc.2 trials
• Akamis Bio1 trial
• Corbus Pharmaceuticals Inc.1 trial
• and 6 more

Running trials

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source

  Contact: Clinical Study Coordinator

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

  Contact: Revolution Medicines Study Director

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· BioNTech SE· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

  Contact: Exelixis Clinical Trials

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Revolution Medicines, Inc.· Source

  Contact: Revolution Medicines Study Director

• Recruiting

  A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

  NCT06500884· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

  NCT05573126· Phase 1/2· Ellipses Pharma· Source

  Contact: Clinical Trials Team

• Active, not recruiting

  Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

  NCT05315258· Phase 2· University of Oxford· Source

• Recruiting

  A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

  NCT04811560· Phase 1/2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

  NCT04603495· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

  NCT04550104· Phase 1· University of Leeds· Source

  Contact: CTRU CONCORDE

• Active, not recruiting

  A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

  NCT04534205· Phase 2/3· BioNTech SE· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Pancreatic cancer3 recruiting
• Lung cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Neuroendocrine tumours1 recruiting

Closed trials

• Completed

  A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck

  NCT04830592· Phase 1· Akamis Bio· Source